There is a desperate need for new treatment options in cancer. Across the solid tumor spectrum, lack of lymphocyte infiltration into the tumor is associated with poor prognosis. Checkpoint therapies are not effective in these patients. In a metastatic setting, therapies that can target multiple nodes of the cancer immunity cycle in a single therapeutic composition will be required to drive T-cell infiltration into tumors and improve outcomes.
Actym was founded with the goal of addressing this need and provide a treatment option to patients with these types of cancer.
